Key Highlights:

• Health Care Select Sector SPDR Fund traded near $174 in late August 2026, with year-to-date gains of 12.55% and one-year returns of 27.14%

• The fund's expense ratio stands at 0.08%, consistent with other SPDR sector products

• Holdings span pharmaceuticals, biotechnology, medical devices, insurers, and health care providers

• Distribution Yield remains moderate, typically between 1% and 2%

Health Care Select Sector SPDR Fund (NYSEARCA:XLV) offers exposure to the health care sector of the S&P 500, spanning pharmaceuticals, biotechnology, medical devices, health insurers, and providers. Managed by State Street, the fund holds a diversified mix of large-cap names across the sector. Its defensive characteristics generally position it differently from cyclical sector funds such as Consumer Discretionary Select Sector SPDR Fund (NYSEARCA:XLY).

The fund's expense ratio is 0.08%, in line with peer SPDR sector products. Health care is often viewed as a defensive sector given relatively stable demand, though the sector faces regulatory, pricing, and patent-expiration risks that can affect individual holdings.

Holdings and Performance

The fund's distribution yield is moderate, typically around 1% to 2%, supported by mature pharmaceutical and device companies with established Cash Flow generation. Holdings include diversified names across pharmaceuticals, insurance, and medical devices, providing a blend of growth and stability within the sector.

As of August 21, 2026, the fund traded near $174 per share, with year-to-date gains of 12.55% and one-year returns of 27.14%, reflecting steady Earnings growth across the sector's major constituents.

Latest Developments

The fund has seen renewed investor interest as Market Participants seek a blend of growth and defensive characteristics, with particular focus on GLP-1 drug development, oncology innovation, and aging demographic trends. Policy debates over drug pricing and insurance regulation have remained ongoing through 2025 and 2026, continuing to influence sector sentiment. Health care ETFs have increasingly served as a relatively stable Equity allocation amid broader macro uncertainty, with steady earnings supporting overall sector performance.

Outlook

The fund's outlook remains tied to continued innovation in drug development, particularly around GLP-1 therapies and oncology treatments, alongside the resolution of ongoing regulatory debates over drug pricing. Aging demographic trends provide a structural tailwind for demand, though policy risk and Patent cliffs at key holdings remain factors that could weigh on individual constituent performance regardless of broader sector strength.